ATE141051T1 - Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie - Google Patents
Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasieInfo
- Publication number
- ATE141051T1 ATE141051T1 AT93302513T AT93302513T ATE141051T1 AT E141051 T1 ATE141051 T1 AT E141051T1 AT 93302513 T AT93302513 T AT 93302513T AT 93302513 T AT93302513 T AT 93302513T AT E141051 T1 ATE141051 T1 AT E141051T1
- Authority
- AT
- Austria
- Prior art keywords
- melatonin
- treatment
- beneficient
- production
- bph
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003987 melatonin Drugs 0.000 title abstract 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 206010020718 hyperplasia Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 102000001419 Melatonin receptor Human genes 0.000 abstract 1
- 108050009605 Melatonin receptor Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 abstract 1
- 229960004535 oxazepam Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86468492A | 1992-04-07 | 1992-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE141051T1 true ATE141051T1 (de) | 1996-08-15 |
Family
ID=25343832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93302513T ATE141051T1 (de) | 1992-04-07 | 1993-03-31 | Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5750557A (de) |
| EP (1) | EP0565296B1 (de) |
| JP (1) | JPH0640939A (de) |
| AT (1) | ATE141051T1 (de) |
| DE (1) | DE69303919T2 (de) |
| DK (1) | DK0565296T3 (de) |
| ES (1) | ES2090861T3 (de) |
| GR (1) | GR3021258T3 (de) |
| HK (1) | HK1006681A1 (de) |
| IL (1) | IL105240A (de) |
| SG (1) | SG41955A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2109695A (en) | 1994-03-30 | 1995-10-23 | Novartis Ag | Screening method using the rzr receptor family |
| EP0748627A3 (de) * | 1995-06-14 | 1997-05-21 | Lilly Co Eli | Melatoninagonisten zur Behandlung von gutartigen Hyperplasieformen der Prostata |
| DK0973790T3 (da) * | 1997-04-07 | 2003-09-22 | Wyeth Corp | Estra-5(10),7-diener med østrogen aktivitet |
| PT1272177E (pt) * | 2000-01-05 | 2007-07-11 | Neurim Pharma 1991 | Método e formulação para o tratamento da resistência aos antihipertensos e condições associadas. |
| RU2221567C2 (ru) * | 2000-08-25 | 2004-01-20 | Санкт-Петербургская медицинская академия последипломного образования | Способ нормализации уровней клеточных факторов роста у мужчин с возрастным андрогенным дефицитом |
| IL144900A (en) * | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| TWI271402B (en) * | 2002-10-15 | 2007-01-21 | Tanabe Seiyaku Co | Large conductance calcium-activated K channel opener |
| IL155666A (en) * | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| MXPA06009377A (es) * | 2004-02-20 | 2007-03-07 | Lifescape Biosciences Inc | Composiciones y metodos para regulacion del sueno. |
| US8940326B2 (en) | 2007-03-19 | 2015-01-27 | Vita Sciences Llc | Transdermal patch and method for delivery of vitamin B12 |
| SG11201903829PA (en) | 2016-10-31 | 2019-05-30 | Neurim Pharma 1991 | Melatonin mini-tablets and method of manufacturing the same |
| US10849856B2 (en) | 2016-10-31 | 2020-12-01 | Neurim Pharmaceuticals Ltd. | Melatonin mini-tablets and method of manufacturing the same |
| CN114982720B (zh) * | 2022-07-26 | 2024-02-13 | 贵州省人民医院 | 一种建立小鼠或大鼠雌雄激素失调型前列腺增生模型的方法 |
| US12274680B2 (en) | 2022-09-13 | 2025-04-15 | II George William Creasy | Treatment of benign prostatic hypertrophy with capsinoids |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) * | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| US4654361A (en) * | 1986-01-27 | 1987-03-31 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Method of lowering intraocular pressure using melatonin |
| EP0330652A1 (de) * | 1987-02-13 | 1989-09-06 | GRAZIOSI, Maurizio | System um schuhunterteile atoxisch zu machen |
| US4855305A (en) * | 1987-03-23 | 1989-08-08 | Applied Medical Research | Compositions and methods of effecting contraception utilizing melatonin |
| GB8727099D0 (en) * | 1987-11-19 | 1987-12-23 | Cellena Cell Eng A G | Compositions containing melantonin/homologues |
| US4945103A (en) * | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
| IN171596B (de) | 1989-06-27 | 1992-11-21 | Cohen Michael | |
| ATE181670T1 (de) | 1991-05-09 | 1999-07-15 | Neurim Pharma 1991 | Melatonin enthaltende arzneimittel |
| US5196435A (en) * | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
-
1993
- 1993-03-31 DK DK93302513.2T patent/DK0565296T3/da active
- 1993-03-31 DE DE69303919T patent/DE69303919T2/de not_active Expired - Fee Related
- 1993-03-31 EP EP93302513A patent/EP0565296B1/de not_active Expired - Lifetime
- 1993-03-31 IL IL10524093A patent/IL105240A/en not_active IP Right Cessation
- 1993-03-31 AT AT93302513T patent/ATE141051T1/de not_active IP Right Cessation
- 1993-03-31 SG SG1995002001A patent/SG41955A1/en unknown
- 1993-03-31 ES ES93302513T patent/ES2090861T3/es not_active Expired - Lifetime
- 1993-04-07 JP JP5080753A patent/JPH0640939A/ja active Pending
- 1993-08-24 US US08/111,014 patent/US5750557A/en not_active Expired - Fee Related
-
1996
- 1996-10-04 GR GR960402609T patent/GR3021258T3/el unknown
-
1997
- 1997-11-24 US US08/976,508 patent/US6048888A/en not_active Expired - Fee Related
-
1998
- 1998-06-23 HK HK98106095A patent/HK1006681A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0565296T3 (da) | 1996-12-09 |
| IL105240A (en) | 1999-04-11 |
| DE69303919T2 (de) | 1997-01-30 |
| US6048888A (en) | 2000-04-11 |
| GR3021258T3 (en) | 1997-01-31 |
| EP0565296B1 (de) | 1996-08-07 |
| EP0565296A1 (de) | 1993-10-13 |
| SG41955A1 (en) | 1997-08-15 |
| JPH0640939A (ja) | 1994-02-15 |
| ES2090861T3 (es) | 1996-10-16 |
| DE69303919D1 (de) | 1996-09-12 |
| US5750557A (en) | 1998-05-12 |
| IL105240A0 (en) | 1993-07-08 |
| HK1006681A1 (en) | 1999-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE141051T1 (de) | Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie | |
| HUT60138A (en) | Process for producing combination compositions suitable for preventing and/or treating benign prostatic hyperplasia | |
| DE69736745D1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
| ATE198706T1 (de) | Polyamin-verbindungen zur behandlung von proliferativer erkrankungen | |
| ATE319447T1 (de) | Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen | |
| DE69424537D1 (de) | Therapeutischer wirkstoff zur behandlung von melanomen | |
| EP1955700A3 (de) | Therapeutische Behandlung androgenrezeptorbedingter Leiden | |
| ATE300292T1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
| DE59508360D1 (de) | Liposomal verkapseltes taxol, seine herstellung und seine verwendung | |
| ATE205086T1 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
| ATE141505T1 (de) | Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht | |
| ATE218860T1 (de) | Verwendung von 3,4-diphenylchromanen zur herstellung eines arzneimittels zur behandlung bzw. vorbeugung des prostatakarzinoms | |
| IT1270993B (it) | Derivati chinzolilamminici attivi come alfa-antagonisti | |
| DE60313603D1 (de) | Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung | |
| DE3685052D1 (de) | Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie. | |
| ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
| RU94040886A (ru) | Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция | |
| ATE135220T1 (de) | Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose | |
| ATE291918T1 (de) | Kombinationstherapie zur behandlung von tumoren | |
| RU94041028A (ru) | Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция | |
| DE69026511D1 (de) | Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis | |
| DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
| ATE91080T1 (de) | Praeparat zum vorbeugen gegen knochenschwund und zur behandlung von knochenschwund. | |
| HUP9901139A3 (en) | Use of melatonin agonists for producing pharmaceutical compositions suitable for treating benign prostatic hyperplasia | |
| MX9710075A (es) | Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |